Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cellectis SA ( (CLLS) ) has provided an update.
On April 13, 2026, Cellectis reported that interim futility data from Allogene Therapeutics’ pivotal ALPHA3 trial in first-line consolidation for large B-cell lymphoma showed strong minimal residual disease clearance for cema-cel, an allogeneic anti-CD19 CAR-T derived from Cellectis’ UCART19 platform and licensed via Servier. The analysis, conducted after 24 patients reached Day 45 assessment, found 58.3% MRD negativity in the cema-cel arm versus 16.7% in the observation arm, with a favorable tolerability profile, reinforcing Cellectis’ thesis that donor-derived allogeneic CAR-Ts can rival or surpass autologous products and potentially unlock up to $340 million in milestones plus royalties under its Servier agreement as the study progresses toward key efficacy readouts through 2028.
The most recent analyst rating on (CLLS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
The score is primarily held back by weak financial performance—ongoing losses, renewed 2025 cash burn, and higher leverage. Technicals add further pressure with price below key moving averages and negative MACD. Valuation provides limited support because earnings are negative and there is no dividend yield.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company specializing in gene-edited cell and gene therapies, with a particular focus on allogeneic, off-the-shelf CAR-T immunotherapies for oncology. Headquartered in Paris with operations in New York and Raleigh, the company controls the value chain from gene editing through in-house manufacturing and is listed on Nasdaq and Euronext Growth.
Average Trading Volume: 42,207
Technical Sentiment Signal: Hold
Current Market Cap: $269.5M
Learn more about CLLS stock on TipRanks’ Stock Analysis page.